Lunesta Pre-Surgery Hold Window: Everything You Need to Know About Eszopiclone Before an Operation

What the label says that matters around an operation

The Lunesta label's dosing instructions are tied to bedtime, not to surgery: take the dose immediately before bedtime with at least 7 to 8 hours remaining before the planned time of awakening [1]. It describes eszopiclone as a CNS depressant and warns of additive effects with benzodiazepines, opioids, tricyclic antidepressants and alcohol, including daytime use, with downward dose adjustment of Lunesta and the other depressant to be considered [1]. Next-day impairment risk rises with the 2 mg and 3 mg doses, with less than 7 to 8 hours of sleep, and with other CNS depressants or drugs that raise eszopiclone levels, and the label advises caution in patients with compromised respiration [1].

Above that sits the boxed warning for complex sleep behaviors — sleep-walking, sleep-driving and other activities while not fully awake — which may occur after the first or any subsequent dose and can cause serious injury or death [1].

The numbers that shape the timing

Peak plasma levels arrive about 1 hour after a dose and the terminal half-life is about 6 hours; at 65 and older the half-life is about 9 hours and exposure is 41% higher [1]. There is no accumulation with once-daily dosing [1]. The label does not translate these figures into a hold time.

Eszopiclone is broken down by CYP3A4 and CYP2E1, and less than 10% of a dose is excreted unchanged in urine [1]. Severe hepatic impairment doubles exposure [1]. Ketoconazole, a potent CYP3A4 inhibitor, increases eszopiclone exposure; the label says other strong inhibitors such as itraconazole, clarithromycin, nefazodone and ritonavir would be expected to behave similarly, and that the dose should not exceed 2 mg with potent CYP3A4 inhibitors [1].

Stopping eszopiclone, and older adults

The label notes that signs and symptoms similar to withdrawal from other CNS depressants have been reported after rapid dose reduction or abrupt discontinuation of sedative-hypnotics [1]. In trials it reports no evidence of a serious withdrawal syndrome, but mild events — anxiety, abnormal dreams, nausea, upset stomach, each at 2% or less — occurred within 48 hours of placebo substitution [1].

For older adults, the label sets a 2 mg maximum in elderly or debilitated patients, and the 2023 AGS Beers Criteria list eszopiclone among medications to avoid in adults 65 and older [1][2].

Label factors that change eszopiclone exposure or effect

The label ties exposure and effect to the dose (1, 2 or 3 mg), the timing of the dose relative to the hours of sleep remaining, other CNS depressants such as opioids, benzodiazepines or alcohol, potent CYP3A4 inhibitors, age 65 or older, and severe liver impairment [1].